Author

Anna A. Sablina

VIB-KU Leuven Center for Cancer BiologyORCID 0000-0001-9526-4014Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Assay:proteomics· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:drug response / drug discovery· 1 Organism:human· 1 Organism:mouse· 1

Frequent Co-Authors

Alexander M.M. EggermontiD· 1 shared Benoit Lechat· 1 shared C. Nunes· 1 shared Edward C. StitesiD· 1 shared Elien HilgertiD· 1 shared Elisa de StanchinaiD· 1 shared Ellen SandersiD· 1 shared Emiel Van BoxeliD· 1 shared

Activity by Year

2024-2024 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 24 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Alexander M.M. EggermontORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologybioRxivPreprintAug 29, 2024

5UTR translational inhibition of neuroblastoma dependency factors using the CR-1-31-B rocaglate

C. Nunes, S.-L. Bekaert, S. Parsa…·Kaat Durinck

This study evaluates CR-1-31-B's effects on neuroblastoma, showing reduced tumor growth and revealing translational inhibition of key dependencies and synergistic effects with CHK1 inhibition.

DOI 10.1101/2024.08.29.610236

humanproteomics

𝕏 PostBluesky

Cancer BiologybioRxivPreprintFeb 27, 2024

Increased dosage of wild-type KRAS protein drives KRAS-mutant lung tumorigenesis and drug resistance

Tonči Ivanišević, Wout Magits, Yan Ma…·Anna A. Sablina

This study shows that increased wild-type KRAS protein dosage in KRAS-mutant lung cancer drives tumor growth and drug resistance, with vascular changes mediated by mTOR pathway activation.

3 citations

mouseproteomics

𝕏 PostBluesky